MAP4K4

Mitogen-activated protein kinase kinase kinase kinase 4

253,523 patent compounds predicted against MAP4K4, 168,853 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL58274	1.00	8/20
SCHEMBL69095	0.67	4/20
SCHEMBL13040	0.66	4/20
SCHEMBL67376	0.64	4/20
SCHEMBL77931	0.62	4/20
SCHEMBL66923	0.60	4/20
SCHEMBL67192	0.60	4/20
SCHEMBL68165	0.59	4/20
SCHEMBL28239	0.46	4/20
SCHEMBL8975	0.38	4/20
SCHEMBL68193	0.67	3/20
SCHEMBL68360	0.67	3/20
SCHEMBL67345	0.64	3/20
SCHEMBL67898	0.64	3/20
SCHEMBL68829	0.64	3/20
SCHEMBL66986	0.59	3/20
SCHEMBL67603	0.59	3/20
SCHEMBL84724	0.59	3/20
SCHEMBL68662	0.58	3/20
SCHEMBL67577	0.58	3/20

Germline variants in MAP4K4 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAP4K4 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAP4K4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...	PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
RASopathy Biorepository	nan	RECRUITING
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease	nan	RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Glutamate Supplementation in Young Men	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP4K4 binder may also engage these)

Protein	Name	Similarity
P97820	—	1.000	P97820 →
TNIK	TRAF2 and NCK-interacting protein kinase	1.000	landscape →
P83510	—	1.000	P83510 →
Q9JM52	—	1.000	Q9JM52 →
MINK1	Misshapen-like kinase 1	1.000	landscape →
Q23356	—	0.999	Q23356 →
F1LP90	—	0.999	F1LP90 →
B3M301	—	0.998	B3M301 →
Q95Q98	—	0.998	Q95Q98 →
Q5HZJ0	—	0.997	Q5HZJ0 →
Q80TZ9	—	0.997	Q80TZ9 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.997	landscape →
B4NBP4	—	0.997	B4NBP4 →
Q09228	—	0.997	Q09228 →
Q6C3D7	—	0.997	Q6C3D7 →
SMARCA2	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2	0.996	landscape →
Q7RZD3	—	0.996	Q7RZD3 →
O61366	—	0.996	O61366 →
Q60V67	—	0.996	Q60V67 →
P83038	—	0.996	P83038 →
Q148W8	—	0.996	Q148W8 →
A2QHV0	—	0.996	A2QHV0 →
A7MBB4	—	0.996	A7MBB4 →
Q6E3D4	—	0.996	Q6E3D4 →
P48479	—	0.996	P48479 →
BMP2K	BMP-2-inducible protein kinase	0.996	landscape →
F1QIC4	—	0.996	F1QIC4 →
O01700	—	0.996	O01700 →
Q19469	—	0.995	Q19469 →
O62090	—	0.995	O62090 →